Start Codon closes new £15 million venture fund
Start Codon, the life science and healthcare business accelerator based in the Milner Therapeutics Institute, today announced that it has closed Start Codon Fund I LP (the “Fund”) at £15 million. The Fund will be used to support Start Codon’s offering to start-ups,...
OncoInnovation: TGIO 2020 Challenge winner
Last month, the Translating Genomics in Oncology (TGIO) 2020 event was co-organized by two programmes of the CRUK Cambridge Centre – Early Detection and OncoInnovation – together with the University Enterprise Zone. The OncoInnovation programme is delivered in the...
Kostas Tzelepis awarded John Goldman Fellowship
We are delighted to announce that Academic in Residence Kostas Tzelepis has been awarded a John Goldman Fellowship from Leukaemia UK to develop and characterize new drugs against the RNA methyltransferase METTL3, which he has previously uncovered as a relevant...
Kathryn Lilley awarded EMBO membership
We are delighted to announce that Kathryn Lilley, Director of the Cambridge Centre for Proteomics, is among 63 leading scientists who have been awarded EMBO membership today – elected on the basis of their scientific excellence and pioneering research. “The new...
Start Codon announces first cohort of companies
Start Codon, the new healthcare accelerator based in the Milner Therapeutics Institute, today announced the first cohort of four companies who were enrolled in the programme this February and will debut at the Milner Symposium event this Friday June 26th and ONHelix...
Eisai join Milner Therapeutics Consortium
We are delighted to announce that Eisai have joined the Milner Therapeutics Consortium, which now includes 8 pharma partners. Eisai is a leading global research and development-based pharmaceutical company headquartered in Japan. Eisai’s corporate mission is defined...
Welcome to the Tzelepis Group
We are delighted that Dr Konstantinos Tzelepis has moved into the Milner Centre for Pathway Analysis as a new Academic in Residence. He brings significant expertise in the identification and characterisation of novel therapeutic targets using a wide range of applied...
A look inside the institute
For the past four years, the Milner Therapeutics Institute has been incubating in the Gurdon Institute – home to the research lab of our Director Tony Kouzarides. This provided essential support as the Milner team was growing and developing key strategic partnerships,...
